Previous preclinical and clinical cardiomiopathy [35] and nephropathy [25] studies have shown anti-inflammatory and cytoprotective effects of CB1 antagonists, due to reduction of tumor necrosis factor-alpha (TNF-α) production and inactivation of nuclear factor-kappaB (NF-κB). This evidence concerns the gene TNF and kidney disorder.